Clinical Momentum Aulos is advancing IL-2 therapeutics with AU-007 and has recently highlighted Phase 2 data in melanoma, presenting a solid opportunity to engage with oncology trial networks, KOLs, and CROs involved in IL-2–based therapies.

Strategic Partnerships The company was formed with strong backers (ATP and Biolojic Design) and has continued to attract funding, signaling a favorable partnership environment for collaboration or co-development deals with biotech and pharma players focusing on immuno-oncology.

Monoclonal IL-2 Focus AU-007 targets IL-2 pathways with reduced regulatory T cell activation, suggesting a differentiable approach that could be licensed or co-developed with firms seeking next-generation immunotherapies for solid tumors.

Emerging Global Access With a California headquarters and a lean team, there may be appetite for regional alliances, including Asia-Pacific or European partners, to accelerate clinical trials, manufacturing partnerships, or later-stage funding rounds.

Data-Driven Outreach Recent industry coverage and AACR activity provide entry points to contact researchers, patient advocacy groups, and conference attendees who are evaluating IL-2–based candidates, enabling targeted outreach for collaboration, advisory roles, or clinical trial support.